{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T14:10:39Z","timestamp":1767276639005,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Next-generation sequencing (NGS) detects somatic mutations in a high proportion of plasma cell dyscrasias (PCD), but is currently not integrated into diagnostic routine. We correlated NGS data with degree of bone marrow (BM) involvement by cytomorphology (BMC), histopathology (BMH), and multiparameter flow cytometry (MFC) in 90 PCD patients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Of the 90 patients the diagnoses comprised multiple myeloma (n\u2009=\u200977), MGUS (n\u2009=\u20097), AL-amyloidosis (n\u2009=\u20094) or solitary plasmocytoma (n\u2009=\u20092). The NGS panel included eight genes <jats:italic>CCND1<\/jats:italic>, <jats:italic>DIS3<\/jats:italic>, <jats:italic>EGR1<\/jats:italic>, <jats:italic>FAM46C<\/jats:italic> (<jats:italic>TENT5C<\/jats:italic>), <jats:italic>FGFR3<\/jats:italic>, <jats:italic>PRDM1<\/jats:italic>, <jats:italic>TP53<\/jats:italic>, <jats:italic>TRAF3<\/jats:italic>, and seven hotspots in <jats:italic>BRAF<\/jats:italic>, <jats:italic>IDH1<\/jats:italic>, <jats:italic>IDH2<\/jats:italic>, <jats:italic>IRF4<\/jats:italic>, <jats:italic>KRAS<\/jats:italic>, <jats:italic>NRAS<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mutations were detected in 64\/90 (71%) of cases. <jats:italic>KRAS<\/jats:italic> (29%), <jats:italic>NRAS<\/jats:italic> (16%) and <jats:italic>DIS3<\/jats:italic> (16%) were most frequently mutated<jats:italic>.<\/jats:italic> At least one mutation\/sample corresponded to a higher degree of BM involvement with a mean of 11% pathologic PC by MFC (range, 0.002\u201362%), and\u2009~\u200950% (3\u2013100%) as defined by both BMC and BMH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The probability of detecting a mutation by NGS in the BM was highest in samples with\u2009&gt;\u200910% clonal PC by MFC, or\u2009&gt;\u200920% PC by BMC\/ BMH. We propose further evaluation of these thresholds as a practical cut-off for processing of samples by NGS at initial PCD diagnosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-022-01346-1","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T23:03:41Z","timestamp":1663887821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-4069","authenticated-orcid":false,"given":"Ekaterina","family":"Rebmann Chigrinova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi A.","family":"Porret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Andres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrud","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Legros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Oppliger Leibundgut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"3","key":"1346_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842\u201354.","journal-title":"Cancer"},{"issue":"15","key":"1346_CR2","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1346_CR3","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1346_CR4","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1038\/bcj.2015.91","volume":"5","author":"T Vu","year":"2015","unstructured":"Vu T, Gonsalves W, Kumar S, et al. Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer J. 2015;5:e363.","journal-title":"Blood Cancer J"},{"issue":"20","key":"1346_CR5","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076\u201384.","journal-title":"Blood"},{"issue":"1","key":"1346_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101.","journal-title":"Cancer Cell"},{"issue":"5","key":"1346_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","volume":"120","author":"BA Walker","year":"2012","unstructured":"Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012;120(5):1077\u201386.","journal-title":"Blood"},{"issue":"12","key":"1346_CR8","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):2604\u201316.","journal-title":"Leukemia"},{"issue":"5","key":"1346_CR9","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/leu.2014.321","volume":"29","author":"T Paino","year":"2015","unstructured":"Paino T, Paiva B, Sayagues JM, et al. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia. 2015;29(5):1186\u201394.","journal-title":"Leukemia"},{"issue":"11","key":"1346_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"12","key":"1346_CR11","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548.","journal-title":"Lancet Oncol"},{"issue":"24","key":"1346_CR12","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"issue":"12","key":"1346_CR13","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","volume":"125","author":"J Corre","year":"2015","unstructured":"Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125(12):1870\u20136.","journal-title":"Blood"},{"issue":"suppl_4","key":"1346_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):52\u201361.","journal-title":"Ann Oncol"},{"issue":"7","key":"1346_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14737159.2017.1332996","volume":"17","author":"M Lionetti","year":"2017","unstructured":"Lionetti M, Neri A. Utilizing next-generation sequencing in the management of multiple myeloma. Expert Rev Mol Diagn. 2017;17(7):653\u201363.","journal-title":"Expert Rev Mol Diagn"},{"issue":"33","key":"1346_CR16","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911\u201320.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1346_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131\u201344.","journal-title":"Cancer Cell"},{"key":"1346_CR18","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.","journal-title":"Nat Commun"},{"issue":"5","key":"1346_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120(5):1060\u20136.","journal-title":"Blood"},{"issue":"7339","key":"1346_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467\u201372.","journal-title":"Nature"},{"issue":"9","key":"1346_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2016.70.6705","volume":"35","author":"S Robiou du Pont","year":"2017","unstructured":"Robiou du Pont S, Cleynen A, Fontan C, et al. Genomics of multiple myeloma. J Clin Oncol. 2017;35(9):963\u20137.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1346_CR22","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1056\/NEJMra1312543","volume":"370","author":"LG Biesecker","year":"2014","unstructured":"Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370(25):2418\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"1346_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cyto.b.21228","volume":"90","author":"M Arroz","year":"2016","unstructured":"Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31\u20139.","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"1346_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","volume":"38","author":"PR Tembhare","year":"2014","unstructured":"Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38(3):371\u20136.","journal-title":"Leuk Res"},{"issue":"2","key":"1346_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/leu.2017.302","volume":"32","author":"KH Chen","year":"2018","unstructured":"Chen KH, Wada M, Pinz KG, et al. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia. 2018;32(2):402\u201312.","journal-title":"Leukemia"},{"issue":"1","key":"1346_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J Mol Diagn. 2017;19(1):4\u201323.","journal-title":"J Mol Diagn"},{"issue":"1","key":"1346_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cyto.b.21271","volume":"90","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, de Tute RM, Haughton J, et al. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds haematological malignancy diagnostic service. Cytom B Clin Cytom. 2016;90(1):54\u201360.","journal-title":"Cytom B Clin Cytom"},{"issue":"11","key":"1346_CR28","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3324\/haematol.2009.009100","volume":"94","author":"B Paiva","year":"2009","unstructured":"Paiva B, Vidriales MB, Perez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica. 2009;94(11):1599\u2013602.","journal-title":"Haematologica"},{"issue":"8","key":"1346_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/leu.2014.13","volume":"28","author":"L Melchor","year":"2014","unstructured":"Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28(8):1705\u201315.","journal-title":"Leukemia"},{"issue":"27","key":"1346_CR30","doi-asserted-by":"publisher","first-page":"24205","DOI":"10.18632\/oncotarget.4434","volume":"6","author":"M Lionetti","year":"2015","unstructured":"Lionetti M, Barbieri M, Todoerti K, et al. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget. 2015;6(27):24205\u201317.","journal-title":"Oncotarget"},{"issue":"1","key":"1346_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","volume":"81","author":"A Neri","year":"1993","unstructured":"Neri A, Baldini L, Trecca D, et al. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81(1):128\u201335.","journal-title":"Blood"},{"issue":"1","key":"1346_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-018-0679-0","volume":"11","author":"B Tessoulin","year":"2018","unstructured":"Tessoulin B, Moreau-Aubry A, Descamps G, et al. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. J Hematol Oncol. 2018;11(1):137.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1346_CR33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.leu.2404524","volume":"21","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Price-Troska T, Gonzalez-Paz N, et al. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007;21(3):582\u20134.","journal-title":"Leukemia"},{"issue":"24","key":"1346_CR34","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner M, Rose AAN, Rajkumar S, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183\u201399.","journal-title":"Oncogene"},{"issue":"6","key":"1346_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587\u201397.","journal-title":"Blood"},{"issue":"2","key":"1346_CR36","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1038\/bcj.2017.19","volume":"7","author":"A Rossi","year":"2017","unstructured":"Rossi A, Voigtlaender M, Janjetovic S, et al. Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood Cancer J. 2017;7(2):e537.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1346_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cancergencyto.2010.08.006","volume":"203","author":"U Bacher","year":"2010","unstructured":"Bacher U, Haferlach T, Kern W, et al. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. Cancer Genet Cytogenet. 2010;203(2):169\u201375.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"1346_CR38","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier S, Park J, Capelletti M, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;9(1):1691.","journal-title":"Nat Commun"},{"issue":"6","key":"1346_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/ejh.12774","volume":"97","author":"A Mikulasova","year":"2016","unstructured":"Mikulasova A, Smetana J, Wayhelova M, et al. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol. 2016;97(6):568\u201375.","journal-title":"Eur J Haematol"},{"issue":"2","key":"1346_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100\u201313.","journal-title":"Nat Rev Clin Oncol"},{"issue":"28","key":"1346_CR41","doi-asserted-by":"publisher","first-page":"26129","DOI":"10.18632\/oncotarget.4674","volume":"6","author":"M Lionetti","year":"2015","unstructured":"Lionetti M, Barbieri M, Todoerti K, et al. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget. 2015;6(28):26129\u201341.","journal-title":"Oncotarget"},{"issue":"4","key":"1346_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2007.06665.x","volume":"138","author":"M Hecht","year":"2007","unstructured":"Hecht M, Heider U, Kaiser M, et al. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol. 2007;138(4):446\u201358.","journal-title":"Br J Haematol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-022-01346-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:07:16Z","timestamp":1663891636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-022-01346-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1186\/s12920-022-01346-1","relation":{},"ISSN":["1755-8794"],"issn-type":[{"type":"electronic","value":"1755-8794"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"20 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were in accordance with the ethical standards of the respective local research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed written consent was obtained from all individual participants included in the study. The approval for access to the clinical and personal patient data used in the study was granted by the Cantonal Ethics Committee of Bern, Switzerland (Kantonale Ethikkommission Bern). The study was approved by the Cantonal Ethic Commission Bern, Switzerland (Kantonale Ethikkommission Bern); Decision number: 2020-01503.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article. Author Ekaterina Rebmann Chigrinova declares that she has no conflict of interest. Author Naomi A. Porret declares that she has no conflict of interest. Author Martin Andres declares that he has no conflict of interest. Author Gertrud Wiedemann declares that she has no conflict of interest. Author Yara Banz declares that she has no conflict of interest. Author Myriam Legros declares that she has no conflict of interest. Author Matthias Pollak declares that he has no conflict of interest. Author Elisabeth Oppliger Leibundgut declares that she has no conflict of interest. Author Thomas Pabst declares that he has no conflict of interest. Author Ulrike Bacher declares that she has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}